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Abstract
Background:  To determine the role of interferon-alpha in controlling HIV infection we
phenotypically and functionally analyzed circulating plasmacytoid dendritic cells (pDC), which are
known to be the highest interferon-alpha producing cells, in 33 perinatally infected HIV+ patients
undergoing standard antiretroviral therapy.
Methods: Circulating pDC were identified by flow cytometry using anti-BDCA-2 monoclonal
antibody and by measuring BDCA-2 mRNA by real-time PCR, while tissue-resident pDC were
identified by immunohistochemistry. mRNA for interferon-alpha and MxA, a gene that is specifically
induced by interferon-alpha, was quantified in peripheral blood cells by real-time PCR, while serum
interferon-alpha protein was measured by ELISA.
Results: While median values of pDC, both in terms of percentage and absolute number, were
not statistically different from age-matched controls, interferon-alpha mRNA was increased in HIV-
infected patients. However, in a group of patients with long disease duration, having a low number
of both pDC and CD4+ lymphocytes and a significant increase of serum interferon-alpha, MxA
mRNA was produced at high level and its expression directly correlated with HIV RNA copy
numbers. Furthermore in patients displaying a low CD4+ blood cell count, a severe depletion of
pDC in the tonsils could be documented.
Conclusion:  HIV replication unresponsive to antiretroviral treatment in perinatal-infected
patients with advanced disease and pDC depletion may lead to interferon-alpha expression and
subsequent induction of MxA mRNA. Thus, the latter measurement may represent a valuable
marker to monitor the clinical response to therapy in HIV patients.
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Background
Over the last 10 years the use of antiretroviral therapy
(ART) in HIV-infected children has resulted in noticeable
benefit as indicated by increased survival [1,2]. However,
poor adherence to prescriptions and the high rates of virus
replication that are characteristic of perinatal infection [3]
often lead to higher virological set points in children com-
pared to adults and lower rates of attainment of undetec-
table viral loads. Therefore, the identification of
immunological correlates of immune reconstitution and
early predictors of antiretroviral failure in HIV-treated
children are needed. Concomitantly with loss of CD4+
cells, children with HIV infection display a profound
impairment of the innate branch of immune system as
indicated by the progressive decrease of circulating den-
dritic cells (DC). DC are a heterogeneous population of
antigen-presenting cells that are required to draw the first
line of host defense against viral infections [4-6]. Two sub-
sets of DC were originally identified in peripheral blood
on the basis of the β2-integrin expression (CD11c
marker): the CD11c+ myeloid DC (mDC) and the CD11c-
plasmacytoid DC (pDC). DC phenotype is defined on the
basis of the two monoclonal antibodies (mAb) BDCA-1
and BDCA-2, which identify blood mDC and pDC,
respectively [7,8]. But, BDCA-1 is also expressed on
monocytes and is not sufficient by itself to define den-
dritic cells [8].
Although blood DC represent less than 1% of total
peripheral blood mononuclear cells (PBMC), they exert a
relevant protective role against invading pathogens by
producing IL-12 and interpheron-alpha (IFN-α) and by
inducing T-cell immunity via presentation of pathogen-
specific antigens on their cell surface [9-13]. IFN-α has
been shown to decrease HIV replication by induction of
IFN-stimulated genes. One such gene is Myxovirus resist-
ance 1, which encodes for the Myxovirus resistance pro-
tein A (MxA), a protein capable of inhibiting the
replication of several viruses, including HIV [14,15].
However, it is controversial whether the increase of IFN-α
secretion, which is observed during disease progression,
contributes to HIV pathogenesis. It has been described
that high levels of IFN-α might exert deleterious effects on
the immune cells by inducing depletion of uninfected
CD4+ lymphocytes [16-18]. Like CD4+ cells, DC express
the receptor machinery necessary for HIV entry, and there-
fore are vulnerable to the detrimental effects of HIV infec-
tion and are functionally impaired in HIV-1-infected
patients [19-24]. Furthermore, pDC loss is believed to be
a predictor of disease progression, of increased risk of
opportunistic infections and of Kaposi sarcoma develop-
ment [19,20,23,24].
It is known that immune reconstitution after ART is
mostly due to newly released lymphocytes from the thy-
mus [25]. However, at the same time, antiretroviral regi-
mens influence DC pool in both adults and children by
completely restoring mDC and only partially recovering
the frequency and function of pDC [21,26].
In this study we evaluated pDC and IFN-α involvement in
a cohort of 33 perinatally HIV-infected patients undergo-
ing ART at various stages of immune-reconstitution, as
determined by analysis of their viral load and CD4+ T-cell
counts.
Patients and methods
Patients and controls
Informed consent was obtained, in accordance with insti-
tutional review board guidelines for the protection of
human subjects, from parents or legal guardians of 33
subjects with perinatal HIV infection (age: from 2 up to 19
years), and from 15 age-matched healthy controls (mean
age: 11.8 years, range: 2–19 years). Patients with acute
infectious diseases or opportunistic infections at the time
of the analysis were excluded from the study.
Circulating pDC and serum IFN-α levels determination
The identification of pDC was performed using Blood
Dendritic Cell enumeration Kit (Miltenyi Biotec GmbH,
Bergish Gladbach, Germany) as previously described [27].
Blood samples were stained simultaneously with anti-
BDCA-2-FITC mAb to identify pDC, anti-CD19-PE-Cy5
and anti-CD14-PE-Cy5 mAbs to exclude B cells and
monocytes, and with a fluorescent cell-impermeant dye
(Dead cells Discriminator), which binds covalently and
irreversibly to nucleic acids of dead cells. After cells stain-
ing, erythrocytes were lysed with ammonium chloride
buffer (Red Blood Cell Lysis), and cells were washed and
fixed using formaldehyde (Fix Solution). Finally, cells
were analyzed by 3-color flow cytometry using FACScan
(Becton Dickinson, San Jose, CA, USA).
The level of IFN-α in the serum was measured by Sand-
wich ELISA using an IFN-α kit (PBL Biomedical Laborato-
ries, Piscataway, NJ, USA) and following the
manufacturer's instructions.
IFN-α, BDCA-2, MxA and TRECs quantification by real-
time PCR
Blood samples (2.5 ml) from patients and controls were
drawn into PAXgene tubes (preAnalytiX GmbH, Hombre-
chtikon, CH), which contain an additive that stabilizes
gene transcription profile by reducing in vitro RNA degra-
dation and minimizing gene induction. RNA was pre-
pared using PAXgene Blood RNA kit following
manufacturer's instructions (preAnalytiX). To remove
contaminating DNA, samples were treated with DNase
(Qiagen Inc. Valencia, CA, USA). Five hundred ng of total
RNA were reverse transcribed with random hexamers in aJournal of Translational Medicine 2008, 6:49 http://www.translational-medicine.com/content/6/1/49
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final volume of 20 μl using the TaqMan RT kit (Applied
Biosystems, Foster City, CA, USA). Real-time PCR analysis
was performed with the GeneAmp 5700 Sequence Detec-
tion System (Applied Biosystems). For IFN-α and BDCA-
2 mRNA measure a pre-developed TaqMan assay, which
included the appropriate primer/probe combination, was
purchased from Applied Biosystems and the test was per-
formed following manufacturer's instructions. For MxA
mRNA quantification we used primers and probes
described by Pachner et al. [28]; the experiments were per-
formed after standardization of the assay in terms of pre-
cision, accuracy and reproducibility [29]. All PCR
reactions were set up in 96-well optical reaction plates
(ABgene, Epsom, UK) in a final volume of 25 μl with 12.5
μl of double concentrated TaqMan universal PCR Master
mix (Applied Biosystems), 3 μl of cDNA, 1.25 μl of
primer/probe mix for IFN-α and BDCA-2 and 600 nM of
primers and 200 nM of probe for MxA. Probe and primer
concentration for the housekeeping gene, Glyceralde-
hyde-3-phosphate dehydrogenase (GAPDH), were respec-
tively 400 and 200 nM. PCR amplification started with a
first step at 50°C for 2 min., followed by an initial heating
at 95°C for 10 min.; samples were then subjected to 45
cycles of denaturation at 95°C for 15 sec and annealing at
60°C for 1 min. Each sample was run in duplicate.
The relative quantification of BDCA-2, IFN-α and MxA
mRNA expression was calculated using the Comparative
cycle threshold (Ct) method according to the following
formula: Normalization Ratio (NR) = 2-ΔΔCtCt. First, for
each sample, ΔCt value was calculated as the Ct of the tar-
get gene minus the Ct of GAPDH and then the ΔΔCt value
was obtained as the difference between the ΔCt of the
sample and the ΔCt of the calibrator. According to the for-
mula, the normalization ratio of the calibrator in each run
is 1. As calibrator in each sample run, we utilized the same
RNA extracted from a single healthy control, and stored at
-80°C.
The quantification of the signal-joint T-cell receptor exci-
sion circles (TRECs) was performed on PBMC separated
by Ficoll-Hypaque density gradient centrifugation using
the standard curve method described by Pirovano et al.
[30].
Immunohistochemistry
Lymph node and tonsil specimens from 8 patients with
HIV infection and from 2 age-matched controls were ana-
lyzed. Each specimen was fixed in buffered formalin and
embedded in paraffin. Sections were stained overnight
with a dilution 1:50 of mouse anti-CD123 mAb (clone
7G3, IgG2a, Becton Dickinson PharMingen Biosciences
Europe, Erembodegem-AALST, Belgium), after inhibition
of endogenous peroxidase activity with 0.3% H2O2 in
methanol for 20 min and heat-induced epitope retrieval
in Tris-EDTA buffer (pH 9.0). Reaction was developed
with the polymer peroxidase conjugated technique
(ChemMate, Dako, Glostrup, DK) and diaminobenzy-
dine as chromogen. Sections were counterstained with
haematoxylin. Cell counting was performed using an
Olympus BX60 microscope equipped with the Olympus
DP-70 digital camera and the Olympus Soft Imaging Sys-
tem Cell-F 2.5; two medium-power fields (corresponding
to 0.3 mm2), selected on the basis of highest content of
positive cells, were evaluated and values were expressed as
mean per one mm2.
Statistical analysis
Since real-time PCR data did not follow a Gaussian distri-
bution, results were expressed as median and range and
analyzed using nonparametric statistical tests. Differences
between values from patients and controls were examined
by Mann-Whitney test, while comparisons between more
than 2 groups of results were assessed by Kruskal-Wallis
ANOVA. In case of significance, Dunn's multiple columns
post-test was applied to compare the sub-groups of treat-
ment. Moreover, Spearman's correlation test was used to
find an association between variables. Two-tailed P values
< 0.05 were considered to be statistically significant.
Results
Clinical and immune features of perinatally HIV- infected 
patients
We evaluated pDC number and function in a population
of 33 perinatally HIV-infected patients, 17 of them were
female and 16 male. CD4+ T lymphocytes ranged from
18.6% to 43.4% (median of 31.6%; Table 1). In particu-
lar, 26 of 33 subjects showed an adequate immune recon-
stitution (Category 1, CD4+%  ≥ 25%), while the
remaining patients had a low number of CD4+ and a high
viral load. They all were under ART at the time of the anal-
ysis according to PENTA guidelines for treatment of HIV
infection in children [31], but the adopted treatment reg-
imen varied from subject to subject depending on the pat-
tern of genotypic resistance and on the adherence to the
therapy [32]. Twenty-four patients were subjected to ART
regimen containing at least one protease inhibitor, 7
patients were treated with a non-nucleoside reverse tran-
scriptase inhibitor, and the remaining 2 patients with two
nucleoside reverse transcriptase inhibitors because of
their poor adherence to other regimens. Despite the adop-
tion of ART, complete suppression of viral load (less than
50 copies/ml) was achieved only in 18 out of 33 patients
(Table 1). This unsatisfactory result was probably the con-
sequence of several contributing reasons, including the
common observance of genotypic resistance in children
failing the treatment, the long length of the disease in
older patients, the slow reduction of viral load following
the introduction of ART in children, and possibly, the dif-Journal of Translational Medicine 2008, 6:49 http://www.translational-medicine.com/content/6/1/49
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ficulty in obtaining long-term adherence to therapy in
adolescents [2,3].
pDC in HIV-infected perinatally HIV-infected patients
We evaluated both the proportion and the absolute
number of pDC in HIV-infected patients by using an assay
that selectively identified the BDCA-2+CD14-CD19- cell
subset. As observed in healthy controls [33], there is an
inverse correlation (r = -0.503, p = 0.003) of pDC values
with age (Figure 1A) and a direct correlation (r = 0.537; p
= 0.002) with the absolute cell number of CD4+ T lym-
phocytes (Figure 1B). The progressive decline of pDC (val-
ues ranging from 33,300 cells/μl to 3,402 cells/μl) can
reflect the "natural" decline in pDC counts during ageing
[33] and is related to the reduction of CD4+ cell number.
This is in agreement with data from Azzoni et al. [34],
demonstrating a greater depletion of pDC in HIV+ chil-
dren with a clinical history of decreasing CD4+ cell per-
centage. Median values of pDC, both in terms of
percentage and absolute number, are not statistically dif-
ferent from those measured in age-matched controls,
although pDC number of HIV+ patients receiving ART is
heterogeneous and varies from extremely low blood
counts up to levels observed in controls (Figure 1C).
Since BDCA-2 was shown to be modulated following
pDC activation [7], we have evaluated the amount of
BDCA-2 mRNA by real-time PCR. Comparable values
were found in patients and healthy controls (median
value of: 1.13 in HIV+ patients vs. 0.93 in healthy children,
p = NS), thus confirming the data obtained by cytofluor-
imetry. We did not assess pDC counts before treatment in
our patients, but based on previous observations we spec-
ulate that pDC counts, possibly lower before treatment,
might be increased after starting the ART.
IFN-α and MxA mRNA induction during HIV infection
Since pDC are specialized cells that produce large
amounts of IFN-α in response to viral infections, we
sought to determine whether HIV infection induces the
Table 1: Clinical and immunological features of HIV-infected children
Patient ID Age (years) Sex CD4+ (%) HIV RNA (copies/ml) CDC
1 16 F 18.6 18527 B 3
2 14 M 18.8 12461 B 2
31 9 F 2 0 5 0 B  3
4 19 F 20 4506 B 2
5 17 F 21.3 78 C2
68 M 2 1 . 9 4 3 6 6 B  2
7 18 M 23.9 65 A 3
8 16 M 25.2 50 B 3
94 F 2 5 . 6 1 6 6 B  1
10 16 F 28.9 50 B 3
11 16 M 29.1 14627 A 2
12 14 F 30 50 B 3
13 11 F 30.2 50 C 2
14 8 M 30.5 50 A 2
15 8 M 30.7 50 A 2
16 4 M 30.8 2214 C 2
17 12 M 31.6 50 C 3
18 17 M 31.9 50 B 3
19a 12 F 32 50 C 2
20 11 F 32.6 50 A 2
21 2 M 33 2154 A1
22 13 F 33.3 50 A 2
23 4 M 33.5 6984 N 1
24 6 M 33.9 50 B 2
25a 16 F 34.5 50 A 2
26 10 M 34.6 77 A 2
27 11 F 38.2 516 B 1
28 11 M 39.3 50 C 1
29 9 F 40.9 50 B 1
30 9 F 41 5674 B 1
31 14 M 42.2 50 C 3
32a 9 F 43.4 50 B 2
33a 15 F 43.4 21422 B 2
aChildren with HCV co-infectionJournal of Translational Medicine 2008, 6:49 http://www.translational-medicine.com/content/6/1/49
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expression of this cytokine. We observed a significant
increase of IFN-α mRNA in PBMC in HIV-infected
patients as compared to healthy control subjects (Figure
1D), suggesting that the chronic infection induces IFN-α
production. Next, we analyzed the expression of MxA
mRNA, which is selectively induced after type-I IFN recep-
tor binding and is a marker for cell responsiveness to IFN-
α [14,35]. We found that MxA mRNA levels were signifi-
cantly increased in HIV-infected patients with abnormal
HIV viral load RNA. Indeed, we observed a direct correla-
tion between MxA expression and HIV RNA copies in HIV
infected patients (Figure 2B), suggesting that a high
number of viral copies may directly influence the induc-
tion of MxA mRNA. Due to the fact that pDC are one of
the principal producers of IFN-α [9] and that MxA is a
marker of type I IFN bioactivity [29,35,36], one might pre-
dict that patients with the largest number of circulating
pDC might express more MxA as compared to age-
matched controls (Figure 2A). On the contrary, we have
observed that higher levels of MxA mRNA are found in
those patients with lower number of circulating pDC, as
indicated by the strong negative correlation between these
two parameters (Figure 2C). In particular, we observed
that 15 patients displayed MxA mRNA levels above the
cut-off, established as the 99th percentile of the distribu-
tion of MxA in healthy control subjects (NR = 2.7, shown
as dotted line in the figure), while the remaining pre-
sented normal MxA mRNA expression. Surprisingly,
patients with MxA mRNA levels above the cut-off are
those with lower numbers of pDC (Figure 3A) and signif-
icantly higher serum levels of IFN-α (Figure 3B). It is of
note that the median level of this cytokine is low in both
(A) Correlation of pDC with age and (B) with CD4+ cell number in ART-treated HIV+ patients Figure 1
(A) Correlation of pDC with age and (B) with CD4+ cell number in ART-treated HIV+ patients. (C) Percentage 
and number of pDC in ART-treated HIV+ children and in age-matched controls (CTRL). (D) Values of IFN-α mRNA, obtained 
by real-time PCR and expressed as normalization ratio (NR), in HIV+ children and CTRL.
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(A) MxA mRNA levels in ART-treated HIV+ children and controls (CTRL) Figure 2
(A) MxA mRNA levels in ART-treated HIV+ children and controls (CTRL). Correlation between MxA mRNA levels 
and HIV viral load (B) and pDC number (C). NR: normalization ratio.
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Immunological parameters of 2 groups of ART-treated HIV+ patients divided according the production of MxA mRNA in MxA- non induced (cut-off value NR < 2.7) and MxA-induced (NR > 2.7) patients Figure 3
Immunological parameters of 2 groups of ART-treated HIV+ patients divided according the production of MxA 
mRNA in MxA-non induced (cut-off value NR < 2.7) and MxA-induced (NR > 2.7) patients. (A) Number of pDC, 
(B) level of serum IFN-α, (C) number of CD4+ lymphocytes, and (D) age of the patients. NR: normalization ratio.
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groups, at levels observed in control children, but it has
been demonstrated that circulating IFN-α is elevated in
the sera just at the moment of HIV antigen appearance
[37]. Moreover, we have also observed that children with
low MxA mRNA (<2.7) below the cut-off show an
increased number of CD4+ lymphocyte (Figure 3C) and
that children with increased MxA mRNA (>2.7) are of
older age (Figure 3D). Since MxA levels do not vary
among ages [29,36], we speculate that increased levels of
MxA mRNA are associated with the length of HIV infec-
tion. Finally, since pDC are present within the thymus
[15] and immune-reconstitution is related to thymic func-
tion [38], we utilized real-time PCR to determine the lev-
els of DNA episomes created in the thymus during T-cell
receptor rearrangement process, known as TRECS. We
observed that TREC values were comparable in HIV-
infected patients and age-matched controls (63,345
TRECs/1 × 106 cells, range: 39,470–173,194 vs. 54,560
TRECs/1 × 106, range: 7,279–299,500), without any
detectable difference between patients with normal or
increased MxA mRNA values (median: 65,925 TRECs/1 ×
106 cells, range: 15,259–155,003 vs. 51,125 TRECs/1 ×
106 cells, range: 17,586–128,900). Similarly, there was no
significant correlation between TRECs and pDC cell
number (data not shown).
pDC in lymphoid tissues of HIV infected children
The decline of circulating pDC, correlating with reduction
of CD4+  and increased IFN-α-dependent MxA gene
expression, in children with advanced HIV infection sug-
gests that pDC might accumulate in secondary lymphatic
tissues [39]. Thus we sought to determine if pDC (identi-
fied as CD123+ cells) are present in lymph nodes and ton-
sils, previously obtained for diagnostic purposes from 8
HIV-infected children. The number of pDC identified in
lymphoid tissues of HIV-infected children was extremely
variable: in some specimens the pDC were abundant in
the interfollicular areas of tonsils and lymph nodes of
both age-matched control subjects (a section of tonsil tis-
sue is shown as representative example in Figure 4A) and
HIV+ patients (a representative example is shown in Figure
4B), while in other HIV-infected children they were
severely depleted (Figure 4C). It should be noted that
pDC were regularly scant in cases showing general lym-
phoid depletion, but they are found to be rare also in cases
with preserved lymphoid tissue, as indicated in Figure 4C.
After plotting the number of pDC detected in lymphoid
tissues of the HIV-infected children against the percentage
of CD4+  or against the HIV-RNA copy number, we
observed a direct correlation between the number of lym-
phatic tissue-resident pDC and CD4+ blood counts, while
there was no correlation with HIV viral load (Figure 4D).
Discussion
The relationship between pDC and CD4+ cells is based on
numerous concordant observations. Following HIV infec-
tion, both cell subsets decrease to levels associated with
increased susceptibility to opportunistic infections [24].
Due to the fact that pDC infiltrate the medulla and the
corticomedullary junction of the thymus, where they
inhibit the replication of the virus [15], and due to the
relationship between HIV infection and the release of
newly generated T lymphocytes from the thymus into
peripheral blood [26], we determined whether there was
a direct relationship between the number of pDC and the
extent of thymic output. We did not observe a correlation
between the number of newly produced T lymphocytes
containing TRECs and the number of pDC, most likely
due to the fact that lymphocyte homeostasis is also regu-
lated in peripheral lymphoid organs, depending on cell
replication and removal [40].
Although higher pDC frequency found in long-term non-
progressors [41] indicate that pDC also have a role in HIV
infection control, a possible link also exists between dis-
ease outcome and reduced pDC number and function,
including a decreased production of IFN-α by pDC during
AIDS progression [24].
High plasma levels of IFN-α can be detected during acute
HIV infection [42], but it is usually barely detectable in
chronic HIV infection due to its short half-life or the rapid
binding to its receptor [43-45]. Accordingly, we found low
serum levels of IFN-α in HIV-infected children, but we
detected significantly increased levels of IFN-α mRNA in
blood cells, suggesting that pDC were in an active state
and potentially capable to deliver the cytokine. The meas-
urement of serum IFN-α and/or IFN-α mRNA might be
used as markers of HIV disease progression and/or of ther-
apy failure [42]. However, the biochemical and biological
properties of the cytokine, including its limited distribu-
tion to blood circulation [17,44], present a serious limita-
tion for its use in a clinical setting. On the contrary, the
evaluation of MxA expression by real-time PCR might
constitute a sensitive and reliable assay for measuring the
extent of IFN-α biological activity. Since MxA mRNA is
induced in response to IFN-α, the expression of MxA is
strictly related to the amount of the cytokine [36]. Indeed,
we have demonstrated that MxA mRNA expression
increased above normal levels in ART-treated HIV-
infected patients who had low numbers of both pDC and
CD4+ cells, suggesting that analysis of MxA induction
could serve as a convenient marker for the evaluation of
extent of pDC immune-restoration. In particular, MxA
mRNA was distinctively increased in HIV-infected chil-
dren with marked depletion of circulating pDC at levels
that were proportional to viral load. This indicates that the
failure to reach viral suppression in children with lowJournal of Translational Medicine 2008, 6:49 http://www.translational-medicine.com/content/6/1/49
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Analysis of tissue pDC Figure 4
Analysis of tissue pDC. pDC counting was performed using an Olympus BX60 microscope equipped with the Olympus DP-
70 digital camera and the Olympus Soft Imaging System Cell-F 2.5. Sections were stained with anti-CD123 by immunoperoxi-
dase technique and counterstained with Mayer's hematoxylin. Magnifications: ×100 (left panels), ×500 (right panels). Two 
medium-power fields (corresponding to 0.3 mm2), selected on the basis of highest content of CD123+ positive cells, were 
evaluated and values were expressed as mean per mm2. Panels A, B and C respectively show tonsil sections from one repre-
sentative healthy child, an HIV-infected child with abundant pDC and a HIV-infected child showing pDC depletion. In panel D 
are the number of pDC (CD123+ cells) of tonsil specimens plotted against the CD4+ cell percentage or the HIV RNA copy 
number of 8 HIV+ children.
Figure 4  
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CD4+ and pDC leads to high increased levels of IFN-α.
According to this hypothesis, we have observed that
serum IFN-α concentration was significantly higher in
HIV-infected children who have increased MxA mRNA
values as compared to patients with MxA expression
below the cut-off.
We have also observed that perinatally HIV-infected
patients with low pDC number displayed the highest lev-
els of MxA mRNA production. We speculate that MxA
induction might be influenced by the interaction of IFN
receptor with its other ligand, IFN-β, by an augmented
IFN-α synthetic activity of fewer circulating pDC, or by the
increased production of IFN-α by sources other than cir-
culating pDC, such as human monocytes [46] or tissue-
resident pDC. Indeed, since HIV infection up-regulates
the pDC chemokine receptor CCR7 [47], these cells might
accumulate in T-cell rich lymphoid tissues, such as tonsils
or lymph nodes. Supporting this Dillon et al. [39] demon-
strated an accumulation of partially activated pDC in lym-
phoid tissues. We did not observe a reduction of
circulating pDC, but the immunohistochemistry results
appear to argue against the hypothesis that enhanced tis-
sue pDC migration is the main factor explaining the
inverse correlation with MxA in perinatally HIV-infected
patients. These issues will need further research, consider-
ing that Biancotto et al. [48] have demonstrated a reduc-
tion of pDC in nodes of chronically infected adults.
Further, the number of pDC in lymphatic tissues of HIV+
individuals might depend on the stage of the disease and
on the extent of pDC activation and susceptibility to HIV-
dependent cell death [39].
High levels of MxA have been reported in peripheral
blood cells of patients with acute viral infections, includ-
ing influenza, herpes, cytomegalovirus, rotavirus, adeno-
virus and RSV [36,49,50], but not in patients with HCV
infection, therefore, this virus is considered a poor inducer
of IFN-α [50,51]. Thus, MxA mRNA levels above the cut-
off found in 3 out of 4 of our patients with HIV-HCV co-
infection were probably correlated to the outcome of HIV
infection.
Conclusion
Although the interpretation of an elevated MxA level
should be made on the basis of the complete clinical and
laboratory data, our results indicate that the analysis of
MxA may represent a valuable tool for the management of
ART in perinatal HIV infection.
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